Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer
April 22, 2024 05:00 ET
|
EVEXTA BIO
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer Feedback from FDA following Type B meeting enables Evexta Bio to move forward in clinical...
Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer
January 04, 2024 10:25 ET
|
EVEXTA BIO
Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer Paul Gineste brings 25 years of experience in clinical development and strategy with leading international...
Diaccurate Announces the Appointment of Scott Filosi as CEO and Corporate Name Change to Evexta Bio
November 06, 2023 08:13 ET
|
DIACCURATE
Diaccurate Announces the Appointment of Scott Filosi as EVEXTA BIOCEO and Corporate Name Change to Evexta Bio Scott Filosi brings more than 30 years of experience in market access and...
Diaccurate présentera des données actualisées de son nouvel inhibiteur de la voie PAM DIACC3010 dans le cancer du sein métastatique ER+ HER2- à l’AACR 2023
April 06, 2023 08:30 ET
|
DIACCURATE
Diaccurate présentera des données actualisées de son nouvel inhibiteur de la voie PAM DIACC3010 dans le cancer du sein métastatique ER+ HER2- à l’AACR 2023 DIACC3010 a une excellente activité...
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023
April 06, 2023 08:30 ET
|
DIACCURATE
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023 DIACC3010 displays broad efficacy in...
Diaccurate est soutenue par Bpifrance pour son Programme DIACC2020 portant sur le développement de nouveaux composés cytotoxiques conjugués à des anticorps thérapeutiques (ADCs)
January 05, 2023 02:00 ET
|
DIACCURATE
La plateforme DIACC2020 ambitionne de mettre au point une nouvelle génération de composés cytotoxiques pouvant être conjugués à des anticorps thérapeutiquesElle s’appuie sur les propriétés uniques du...
Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)
January 05, 2023 02:00 ET
|
DIACCURATE
The DIACC2020 platform aims to develop a new generation of cytotoxic compounds to be conjugated to therapeutic antibodies The Program stems from the unique properties of its proprietary compound...
DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and immunotherapy
January 12, 2021 13:24 ET
|
DIACCURATE
BIOKINESIS absorption by DIACCURATE occurred early December 2020Dr. Dominique BRIDON leads the new entityDIACCURATE is now developing 3 programs in cancer and immunotherapyDIACCURATE will be...